ImpediMed Completes $2.1M Oversubscribed SPP Following $13.2M Placement
ImpediMed raises $2.1 million in oversubscribed Share Purchase Plan
ImpediMed Limited (ASX: IPD) has completed its oversubscribed Share Purchase Plan, raising $2.1 million following closure on 5 June 2026. The SPP follows a $13.2 million institutional placement announced in May, bringing the combined capital raise to $15.3 million. Applications totalled $3.5 million against an initial $2.0 million target, exceeding the initial target by $1.5 million.
ImpediMed’s $15.2 million capital raise was structured across two tranches, with the institutional placement priced at $0.010 per share and the SPP opening to retail shareholders on the same terms, alongside an option structure creating a potential additional funding pathway of up to $32.7 million if fully exercised.
The Board resolved to accept up to $0.1 million in oversubscriptions above the initial target. The issue price was set at $0.007 per SPP Share, representing a 2.5% discount to the 5-day VWAP up to and including the closing date. The company expects to issue 300 million SPP Shares under the completed raise, with a scale-back applied on a pro rata basis where applications exceeded allocations.
Strong retail investor demand signals confidence in ImpediMed’s growth trajectory and validates the institutional placement pricing established in May.
When big ASX news breaks, our subscribers know first
What is a Share Purchase Plan and why do companies use them?
A Share Purchase Plan is a capital raising mechanism that allows existing shareholders to purchase additional shares without incurring brokerage, commissions, or other transaction costs. ImpediMed’s SPP offered eligible shareholders in Australia and New Zealand the opportunity to apply for up to $100,000 of new fully paid ordinary shares.
When demand exceeds the initial target, boards may accept additional applications. Oversubscription occurs when total applications surpass the amount the company initially planned to raise. In ImpediMed’s case, the Board exercised its discretion to accept $0.1 million in oversubscriptions, bringing the total SPP raise to $2.1 million.
When oversubscription is accepted but still below total demand, a scale-back is applied on a pro rata basis. This ensures all participating shareholders receive a proportional allocation rather than some receiving their full application while others receive nothing.
SPPs democratise capital raising by giving retail investors access to the same pricing as institutional investors, often at a discount to market price. This structure maintains equity between institutional and retail shareholders whilst broadening the shareholder base.
Option entitlements sweeten the deal for SPP participants
SPP participants will receive a two-tier option structure: one Attaching Option plus one Follow-on Option per SPP Share subscribed for. The Follow-on Option becomes exercisable following the valid exercise of the first Attaching Option, creating a cascading participation mechanism.
Under this structure, the 300 million SPP Shares to be issued will generate 300 million Attaching Options plus 300 million Follow-on Options. Placement participants also receive options under similar terms, broadening the application of this incentive structure across both institutional and retail investors.
The issue of all options under both the SPP and the Placement will be subject to shareholder approval at an Extraordinary General Meeting scheduled for 11 June 2026. Following approval, the company will apply for quotation of all shares and options on the ASX.
Key dates and shareholder approval requirements
The Extraordinary General Meeting will take place on 11 June 2026 at 11:00am (AEST) to approve Tranche 2 of the Placement and all option issuances under both the SPP and the Placement. Shareholders may attend in person at Clifford Chance’s Sydney offices or online via the company’s investor portal.
Following shareholder approval, SPP Shares and all Attaching Options and Follow-on Options are expected to be issued on 15 June 2026, with trading commencing on 16 June 2026. Holding statements will be dispatched to successful applicants on the same day trading begins.
| Event | Date |
|---|---|
| SPP Closed | 5 June 2026 |
| EGM (Shareholder Approval) | 11 June 2026 |
| Share & Option Issue | 15 June 2026 |
| Trading Commences | 16 June 2026 |
| Holding Statements Dispatched | 16 June 2026 |
The issue price under the SPP was determined in accordance with the Prospectus terms and set at $0.007 per SPP Share, calculated as a 2.5% discount to the 5-day VWAP of shares traded on the ASX up to and including the SPP closing date.
Chair thanks shareholders for strong support
Chair of the Board Christine Emmanuel-Donnelly acknowledged the shareholder response and positioned the capital raise as funding the company’s next growth phase.
Christine Emmanuel-Donnelly, Chair of the Board
“We are very pleased with the strong response to the Share Purchase Plan, which reflects the continued confidence and support of our shareholders. On behalf of the Board, I would like to sincerely thank our investors for their participation and commitment to the Company. This level of support is greatly appreciated and positions us well for the next phase of our growth strategy.”
The combined Placement and SPP capital raised totals $15.3 million, strengthening the company’s balance sheet as it pursues commercial expansion of its SOZO Digital Health Platform.
The next major ASX story will hit our subscribers first
Combined capital raise totals over $15 million
The $13.2 million institutional placement combined with the $2.1 million SPP brings total capital raised to $15.3 million. The funds position ImpediMed to execute its growth strategy with the SOZO Digital Health Platform, which uses bioimpedance spectroscopy technology for clinical assessment of lymphoedema, heart failure, and protein calorie malnutrition.
SOZO platform expansion into heart health and weight management targets a combined addressable market exceeding $1.5 billion, with dedicated commercial teams now operational across 17 of the 20 largest US integrated delivery networks.
Headquartered in Sydney with US and European operations, ImpediMed produces medical technology that is FDA-cleared, CE-marked, and ARTG-listed for multiple indications. The SOZO platform is sold in select markets globally through a SaaS subscription-based business model.
In March 2024, the NCCN Clinical Practice Guidelines In Oncology continued to reference bioimpedance spectroscopy as the recommended objective tool to screen at-risk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex technology, ImpediMed is the only company to offer FDA-cleared technology using bioimpedance spectroscopy for lymphoedema clinical assessment.
Want the Next Healthcare Breakthrough in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX healthcare news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to start receiving alerts the moment market-moving announcements hit the ASX.